Phase III clinical trial - Gynécologie - Ovaires
FORWARD-1
Gynécologie - Ovaires
Ouvert depuis le: 07.27.2024
Site: Saint-Cloud
Public cible
Adulte
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Description de l'essai
This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of IMGN853 to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced EOC, primary peritoneal cancer and/or fallopian tube cancer.
Liens utiles
ANNE DONNADIEU
Investigateur principal